Case Information

A lawsuit called In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK is currently pending in the United States District Court for the District of New Jersey (“the Court”). The Lawsuit alleges that Defendants (a complete list of these Defendants is available here) violated numerous state laws by manufacturing, producing and/or selling Valsartan or VCDs that were contaminated with probable genotoxic human carcinogens in the form of nitrosamines, N-nitrosodimethylamine (“NDMA”) and N-nitrosodiethylamine (“NDEA”). This Lawsuit does not include personal injury claims. The Court has not decided whether Defendants did anything wrong and the Defendants have denied any wrongdoing and asserted various legal defenses.

No money or benefits are available now because the Court has not yet decided whether Defendants did anything wrong, and the two sides have not settled the case. There is no guarantee that money or benefits will ever be obtained. For more information on the current status of the case, click here. The United States District Court for the District of New Jersey approved notice for this case, including this website.  To view the Court’s website for this case, click here.

Who Is a Class Member?

Third Party Payor Class
All Third Party Payors that, from at least January 1, 2012 through the date of final recall as of November 10, 2021, paid any amount of money in any of the 50 states, Puerto Rico or the District of Columbia for a valsartan-containing drug that was manufactured, distributed, or sold in the United States by any Active Pharmaceutical Ingredient, Finished Dose, Wholesaler, or Pharmacy Defendant.  Click here for additional information about this class.
In addition to the above Third Party Payor Class, there are two classes relating to individual consumers.  See descriptions below and separate notices for more details.
Consumer Economic Loss Class	Medical Monitoring Class
All individuals in the United States and its territories and possessions who, since at least January 1, 2012 through the date of final recall as of November 10, 2021, paid any amount of money for a valsartan-containing drug (intended for personal or household use) that was manufactured, distributed, or sold by any Defendant. Click here for additional information about this class.	Individuals residing in the United States and its territories and possessions (except Mississippi, New Hampshire, North Carolina, and North Dakota) who consumed a sufficiently high Lifetime Cumulative Threshold of NDMA, NDEA, or other nitrosamine, in generic valsartan-containing drugs manufactured by or for Defendants, at least since January 1, 2012. Click here for additional information about this class.

 

Your Legal Rights and Options

Register for Updates

If you believe you are eligible, you can complete a simple form here to be informed about case updates. This will help us contact you in the event of any future settlement or judgment.